AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Biohit Oyj

Report Publication Announcement • Jan 5, 2017

3304_rns_2017-01-05_34bdfc24-60eb-41cc-b71e-94ba4272da05.html

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Disclosure 348141

Biohit Oyj - Company Announcement

Biohit Oyj CEO Semi Korpela takes sick leave

Biohit Oyj Stock Exchange Release January 5, 2017 at 1:00 pm local time (EEST) Starting from January 5, 2017 Biohit Oyj´s CEO Semi Korpela will take a sick leave of approximately one month related to pneumonia. During Semi Korpela´s sick leave, his deputy will be Biohit Oyj`s CFO Niklas Nordström. Board of Directors Additional information: Osmo Suovaniemi, Chairman of the Board of Directors tel. +358 9 773 861 [email protected] www.biohithealthcare.com Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com